Eli Lilly stock target cut, retains Buy rating on growth potential
Guggenheim analysts revised their price target for Eli Lilly (NYSE:LLY) shares, reducing it to $973.00 from the previous $995 ...
Mega M&A at JP Morgan Conference 2025 — is biopharma M&A poised for a rebound?
Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.
TMCnet4 小时
Weekly Roundup: 15 Health Press Releases You Need to See
A roundup of the most newsworthy healthcare announcements from PR Newswire this week, including the FDA's nicotine reduction ...
Here's the article based on the provided information:
This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...